CR10279A - Combinacion sinergica de inhibidores de receptores h2, silicon inerte y un complejo aluminato de hidroximagnesio. - Google Patents

Combinacion sinergica de inhibidores de receptores h2, silicon inerte y un complejo aluminato de hidroximagnesio.

Info

Publication number
CR10279A
CR10279A CR10279A CR10279A CR10279A CR 10279 A CR10279 A CR 10279A CR 10279 A CR10279 A CR 10279A CR 10279 A CR10279 A CR 10279A CR 10279 A CR10279 A CR 10279A
Authority
CR
Costa Rica
Prior art keywords
hydroximagnesium
inhibitors
receiver
aluminate complex
inert silicon
Prior art date
Application number
CR10279A
Other languages
English (en)
Inventor
Armenta Maria Elena Garcia
Ochoa Victor Guillermo Alvarez
Murillo Josefina Santos
Armenta Patricia Garcia
Original Assignee
World Trade Imp Export Wtie A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from MXPA/A/2006/002749A external-priority patent/MXPA06002749A/es
Application filed by World Trade Imp Export Wtie A G filed Critical World Trade Imp Export Wtie A G
Publication of CR10279A publication Critical patent/CR10279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion esta relacionada con la industria farmceutica en genral y con la industria farmaceutica preparadora de medicamentos para la prevencion y/o tratamiento de la enfermedad acido peptica y sintomas relacionados con la produccion excesiva de acido en el estomago, ademas de contribuir a la cicatrizacion, prevencion de recidivas sintomaticas y complicaciones, en particular.
CR10279A 2006-03-09 2008-09-09 Combinacion sinergica de inhibidores de receptores h2, silicon inerte y un complejo aluminato de hidroximagnesio. CR10279A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA/A/2006/002749A MXPA06002749A (es) 2006-03-09 Combinacion sinergica de inhibidores de receptores h2, silicon inerte y un complejo aluminato de hidroximagnesio

Publications (1)

Publication Number Publication Date
CR10279A true CR10279A (es) 2008-10-10

Family

ID=40459929

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10279A CR10279A (es) 2006-03-09 2008-09-09 Combinacion sinergica de inhibidores de receptores h2, silicon inerte y un complejo aluminato de hidroximagnesio.

Country Status (5)

Country Link
EP (1) EP1992345A4 (es)
BR (1) BRPI0621391A2 (es)
CR (1) CR10279A (es)
EC (1) ECSP088726A (es)
WO (1) WO2007102726A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200038376A1 (en) 2016-11-01 2020-02-06 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form comprising an histamine h2-receptor antagonist and an antacid
US11433024B2 (en) 2018-04-27 2022-09-06 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2166731A1 (en) * 1993-07-06 1995-01-19 Robert T. Sims H2 antagonist-alginate-antacid combinations
WO1995001780A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
DE4444052A1 (de) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US6537525B1 (en) * 1997-01-29 2003-03-25 Douglas H. West Medicated chewing-gum
US6579545B2 (en) * 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent

Also Published As

Publication number Publication date
EP1992345A1 (en) 2008-11-19
WO2007102726A1 (es) 2007-09-13
BRPI0621391A2 (pt) 2011-12-06
ECSP088726A (es) 2008-10-31
EP1992345A4 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
BR112012001297A2 (pt) conector.
AR092844A1 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
JO2641B1 (en) Pharmaceutical compounds containing calcium rosofastatin
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
WO2007115620A3 (de) Neuartige cyclobutyl-verbindungen als kinase-inhibitoren
WO2007115269A3 (en) Orally bioavailable caffeic acid related anticancer drugs
UA106037C2 (uk) Модулятори ampk (амф-активованої протеїнкінази)
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2007059905A3 (en) Thienopyrimidines treating inflammatory diseases
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29161A1 (es) Nuevos heterociclos
WO2010092090A3 (en) Novel salts of sitagliptin
BR112013017600A2 (pt) preparação para desintegração rápida, método para produzir uma preparação para desintegração rápida, preparação para absorção pela mucosa oral, método e droga para a profilaxia e / ou tratamento de um distúrbio bipolar, e, composto
BRPI0606322A2 (pt) formulações intravenosas de inibidores de pde-5
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole
WO2011159976A3 (en) Arthritis treatment
CR10279A (es) Combinacion sinergica de inhibidores de receptores h2, silicon inerte y un complejo aluminato de hidroximagnesio.
JP2011512394A5 (es)
TW200728281A (en) Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
EP2384745A3 (en) Modified release pharmaceutical compositions of dexlansoprazole
DK1984001T3 (da) Fikseret dosisassociation af phytat og zink
WO2007003435A3 (de) Verwendung von aktivatoren der löslichen guanylatzyklase zur förderung der wundheilung